2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.83(Poster) Treatment sequencing in the VISION study of tepotinib in patients with MET exon 14 (METex14) skipping NSCLC

PP01.83(Poster) Treatment sequencing in the VISION study of tepotinib in patients with MET exon 14 (METex14) skipping NSCLC

Back to course

Pdf Summary

The VISION study evaluated the sequencing of treatment in patients with non-small cell lung cancer (NSCLC) who had MET exon 14 (METex14) skipping. The study found that tepotinib, a MET inhibitor, demonstrated strong and lasting efficacy in treating METex14 skipping NSCLC. The study showed that tepotinib was effective as a first-line treatment, supporting its early use in the treatment sequence. It was also found that tepotinib was more effective than immune-oncology (IO)-based regimens in patients with a smoking history. The study also observed efficacy in second-line patients regardless of prior therapies, including IO and/or platinum-based chemotherapy.<br /><br />The study also compared the treatment sequencing in the VISION study with other trials. It was noted that almost half of the elderly population in the VISION study received subsequent treatment, which was higher than the rates reported in other trials. Shorter duration of response and progression-free survival outcomes were observed with platinum-based chemotherapy and IO-containing regimens, supporting the use of tepotinib in patients with METex14 skipping NSCLC.<br /><br />The study also looked at the use of MET inhibitors post-tepotinib. It found that a high number of patients received subsequent MET inhibitor therapy, and there was a clinical benefit when the rechallenge occurred following a break in MET inhibitor use. The study highlighted the need for additional treatment options for METex14 skipping NSCLC, as there are currently no other specific treatments approved for this subtype of lung cancer.<br /><br />Overall, the VISION study demonstrated the efficacy of tepotinib in patients with METex14 skipping NSCLC and provided insights into treatment sequencing and the use of MET inhibitors in this patient population.

Asset Subtitle

Matthew Lee

Keywords

VISION study

METex14 skipping NSCLC

tepotinib

first-line treatment

immune-oncology

smoking history

second-line patients

MET inhibitors

clinical benefit

treatment options